Journal of Bioequivalence & Bioavailability

Targeted Drug Delivery Systems Principles Mechanisms and Emerging Applications in Modern Therapeutics

Nathaniel Brooks ^* Department of Pharmaceutical Sciences, University of Melbourne, Melbourne, Australia
^*Correspondence: Nathaniel Brooks, Department of Pharmaceutical Sciences, University of Melbourne, Melbourne, Australia, Email:

Received: 12-May-2026 , Manuscript No. JBB-26-31803; Editor assigned: 14-May-2026 , Pre QC No. JBB-26-31803 (PQ); Reviewed: 29-May-2026 , QC No. JBB-26-31803; Revised: 05-Jun-2026 , Manuscript No. JBB-26-31803 (R); Published: 12-Jun-2026 , DOI: 10.35248/0975-0851.26.18.700

Description

Targeted drug delivery systems represent an advanced approach in pharmaceutical sciences aimed at directing therapeutic agents specifically to diseased sites while minimizing distribution to healthy tissues. This strategy is designed to improve therapeutic outcomes by increasing drug concentration at the intended site of action and reducing systemic exposure that may lead to unwanted effects. The concept has gained significant attention in recent decades due to advancements in nanotechnology, molecular biology, and material sciences, which have enabled the design of carriers capable of precise localization and controlled release. The fundamental principle underlying targeted drug delivery involves the selective interaction between drug carriers and specific biological markers present at disease sites. These markers may include receptors, antigens, enzymes, or altered physiological conditions such as pH and redox potential.

By exploiting these differences, drug delivery systems can achieve preferential accumulation in pathological tissues such as tumors, inflamed regions, or infected cells. This selective targeting is often achieved through passive or active mechanisms, each contributing differently to drug distribution profiles. Passive targeting relies primarily on physiological characteristics of diseased tissues. In tumor therapy, for example, the enhanced permeability and retention effect allows nanoscale carriers to accumulate in cancerous tissues due to leaky vasculature and impaired lymphatic drainage. This phenomenon has been widely utilized in the design of liposomes, polymeric nanoparticles, and micelles.

These carriers can encapsulate therapeutic agents and release them gradually within the tumor microenvironment, leading to increased local drug exposure compared to conventional formulations.Active targeting, in contrast, involves the modification of drug carriers with ligands that can specifically bind to receptors expressed on target cells. These ligands may include antibodies, peptides, aptamers, or small molecules. Once administered, the ligand-functionalized carrier recognizes and binds to its corresponding receptor, facilitating receptormediated endocytosis and intracellular drug release. This strategy enhances specificity and allows for more precise control over drug distribution at the cellular level.The success of targeted delivery systems depends on multiple physicochemical factors, including particle size, surface charge, hydrophobicity, and stability in biological fluids. Particle size influences circulation time and tissue penetration, while surface charge affects interaction with plasma proteins and cellular membranes. Surface modification with hydrophilic polymers such as polyethylene glycol can reduce opsonization and prolong systemic circulation, enhancing the probability of reaching the target site. Stability in biological environments is also essential to prevent premature drug release and ensure delivery to the intended location.

Pharmacokinetic behavior of targeted delivery systems differs significantly from conventional dosage forms. These systems often demonstrate altered absorption, distribution, metabolism, and excretion profiles due to their size, composition, and surface characteristics. The encapsulated drug may exhibit prolonged circulation time, reduced clearance, and modified biodistribution. These changes contribute to improved therapeutic index and reduced dose frequency in certain applications. Understanding these pharmacokinetic modifications is essential for designing effective delivery strategies and predicting in vivo performance.

Targeted drug delivery has found applications in oncology, infectious diseases, cardiovascular disorders, and neurological conditions. In cancer therapy, targeted systems aim to selectively destroy malignant cells while sparing normal tissues, thereby reducing adverse effects commonly associated with chemotherapy. In infectious diseases, these systems can deliver antimicrobial agents directly to infected cells or tissues, improving efficacy against resistant pathogens. In cardiovascular and neurological applications, targeted delivery helps overcome biological barriers such as atherosclerotic plaques or the blood–brain barrier, enabling site-specific therapy.

Despite significant progress, several challenges remain in the clinical translation of targeted drug delivery systems. Biological barriers, immune recognition, and variability in patient physiology can affect the efficiency of targeting. Manufacturing complexity and scalability also present obstacles in large-scale production. Regulatory evaluation requires comprehensive characterization of physicochemical properties, stability, toxicity, and pharmacokinetics to ensure safety and efficacy. Continued research is focused on improving carrier design, enhancing targeting accuracy, and developing responsive systems that release drugs in response to specific stimuli.

In Conclusion, Targeted drug delivery systems offer a refined approach to therapy by enabling selective localization of drugs to diseased tissues while limiting systemic exposure. Through the integration of passive and active targeting strategies, along with advances in carrier design and nanotechnology, these systems have enhanced the precision of pharmacotherapy. Continued development in material science, molecular targeting, and controlled release technologies is expected to further expand their clinical utility. These advancements support more effective treatment strategies across a wide range of diseases while improving drug performance characteristics and patient outcomes.